cell lines

Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in P53-Dependent or -Independent Manners.

Published April 27, 2013

Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners.

PLoS One. 2013; 8(4): e61537
Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H… Continue reading →

Consanguineous Mating, Specialization, and the Environment: How Multiple Variable Interactions Affect the Evolution of Dioecy.

Published April 27, 2013

Consanguineous mating, specialization, and the environment: How multiple variable interactions affect the evolution of dioecy.

Am J Bot. 2013 Apr 25;
Sinclair JP, Maxwell GD, Freeman DC

• Premise: The evolution of dioecy in plants is usually modeled as… Continue reading →

Anti-Pancreatic Cancer Deliverables From Sea: First-Hand Evidence on the Efficacy, Molecular Targets and Mode of Action for Multifarious Polyphenols From Five Different Brown-Algae.

Published April 25, 2013

Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae.

PLoS One. 2013; 8(4): e61977
Aravindan S, Delma CR, Thirugnanasambandan SS, Herman TS, Aravindan N

Pancreatic… Continue reading →

Luteolin Is a Novel P90 Ribosomal S6 Kinase (RSK) Inhibitor That Suppresses Notch4 Signaling by Blocking the Activation of Y-Box Binding Protein-1 (YB-1).

Published April 18, 2013

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).

Oncotarget. 2013 Feb; 4(2): 329-45
Reipas KM, Law JH, Couto N, Islam S, Li Y, Li… Continue reading →

Rapid Cytotoxicity of Antimicrobial Peptide Tempoprin-1CEa in Breast Cancer Cells Through Membrane Destruction and Intracellular Calcium Mechanism.

Published April 13, 2013

Rapid Cytotoxicity of Antimicrobial Peptide Tempoprin-1CEa in Breast Cancer Cells through Membrane Destruction and Intracellular Calcium Mechanism.

PLoS One. 2013; 8(4): e60462
Wang C, Tian LL, Li S, Li HB, Zhou Y, Wang H, Yang QZ, Ma LJ, Shang… Continue reading →

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia.

Published April 5, 2013

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia.

AAPS J. 2013 Apr 3;
Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES

Timing… Continue reading →

The Efficacy and Safety of Sertaconazole Cream (2 %) in Diaper Dermatitis Candidiasis.

Published April 4, 2013

The Efficacy and Safety of Sertaconazole Cream (2 %) in Diaper Dermatitis Candidiasis.

Mycopathologia. 2013 Apr 2;
Bonifaz A, Tirado-Sánchez A, Graniel MJ, Mena C, Valencia A, Ponce-Olivera RM

AIM: Diaper dermatitis (DD) is an inflammatory irritating condition… Continue reading →

Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA.

Published April 3, 2013

Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA.

Drug Deliv Transl Res. 2013 Apr 1; 3(2): 183-194
Lu S, Labhasetwar V

Cancer stem cell (CSC) population in solid human… Continue reading →

CXCR4 Expression and Treatment With SDF-1? or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells.

Published April 2, 2013

CXCR4 Expression and Treatment with SDF-1? or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells.

Transl Oncol. 2013 Apr; 6(2): 124-32
Heckmann D, Maier P, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Allgayer H

Signaling through stromal… Continue reading →

A Retrospective Audit to Evaluate the Effect of the Change in Midazolam Concentration From 10 Mg/5 Ml to 5 Mg/5 Ml Ampoules on Midazolam Doses Given to Sedation Patients Following the Rapid Response Report (RRR).